Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
434 questions in 75 reviews · Metabolic and Endocrine Disorders
current versionsNo studies 434 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Body weight (kg) Non‐nutritive sweeteners for diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Socioeconomic effects Non‐nutritive sweeteners for diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Diabetes complications Non‐nutritive sweeteners for diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality Non‐nutritive sweeteners for diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR NNS versus sugar Non‐nutritive sweeteners for diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR NNS versus nutritive, low‐calorie sweetener Non‐nutritive sweeteners for diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs insulin All‐cause mortality Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs sulphonylureas Health‐related quality of life Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs sulphonylureas End‐stage renal disease Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs thiazolidinediones Health‐related quality of life Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs insulin Serious adverse events Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs thiazolidinediones End‐stage renal disease Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs dipeptidyl‐peptidase 4 inhibitors Health‐related quality of life Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs dipeptidyl‐peptidase 4 inhibitors End‐stage renal disease Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs glucagon like peptide‐1 analogues Health‐related quality of life Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs glucagon like peptide‐1 analogues End‐stage renal disease Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs meglitinides All‐cause mortality Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs meglitinides Health‐related quality of life Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs meglitinides Cardiovascular mortality Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs insulin Cardiovascular mortality Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs meglitinides Non‐fatal myocardial infarction Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs meglitinides Non‐fatal stroke Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs meglitinides End‐stage renal disease Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs insulin Non‐fatal myocardial infarction Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs insulin Non‐fatal stroke Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs insulin End‐stage renal disease Metformin monotherapy for adults with type 2 diabetes mellitus (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy All‐cause mortality · people at increased risk of developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy Cardiovascular mortality · people at increased risk of developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy Socioeconomic effects · people at increased risk of developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention All‐cause mortality · people at increased risk for developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention Cardiovascular mortality · people at increased risk for developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention Non‐fatal myocardial infarction/stroke · people at increased risk for developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy Metformin · people at increased risk of developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention Health‐related quality of life · people at increased risk for developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention Socioeconomic effects · people at increased risk for developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs placebo Health‐related quality of life · people at increased risk for developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs placebo Socioeconomic effects · people at increased risk for developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy Acarbose · people at increased risk of developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs no intervention Cardiovascular mortality · people at increased risk of developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs no intervention Non‐fatal myocardial infarction/stroke · people at increased risk of developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs no intervention Health‐related quality of life · people at increased risk of developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs no intervention Socioeconomic effects · people at increased risk of developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy Repaglinide · people at increased risk of developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy Serious adverse events (N) · people at increased risk of developing T2DM Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table for metformin vs diet and exercise or another antidiabetic drug All‐cause mortality (N) · people at increased risk for developing type 2 diabetes Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at… (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table for metformin vs diet and exercise or another antidiabetic drug Cardiovascular mortality · people at increased risk for developing type 2 diabetes Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at… (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table for metformin vs diet and exercise or another antidiabetic drug Acarbose · people at increased risk for developing type 2 diabetes Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at… (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table for metformin vs diet and exercise or another antidiabetic drug Intensive diet plus exercise · people at increased risk for developing type 2 diabetes Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at… (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table for metformin vs diet and exercise or another antidiabetic drug Socioeconomic effects · people at increased risk for developing type 2 diabetes Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at… (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table for metformin plus intensive diet and exercise vs intensive diet and exercise Serious adverse events · people at increased risk for developing type 2 diabetes Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at… (2019) · Cochrane | no estimate extracted | NR | No studies |